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Protease-mediated maturation of HIV-1 virus particles is essential for virus infectivity. Maturation occurs concomitant with
immature virus particle release and is mediated by the viral protease (PR), which sequentially cleaves the Gag and Gag-Pol
polyproteins into mature protein domains. Maturation triggers a second assembly event that generates a condensed conical capsid
core. The capsid core organizes the viral RNA genome and viral proteins to facilitate viral replication in the next round of infection.
The fundamental role of proteolytic maturation in the generation of mature infectious particles has made it an attractive target
for therapeutic intervention. Development of small molecules that target the PR active site has been highly successful and nine
protease inhibitors (PIs) have been approved for clinical use. This paper provides an overview of their development and clinical
use together with a discussion of problems associated with drug resistance. The second-half of the paper discusses a novel class of
antiretroviral drug termed maturation inhibitors, which target cleavage sites in Gag not PR itself. The paper focuses on bevirimat
(BVM) the first-in-class maturation inhibitor: its mechanism of action and the implications of naturally occurring polymorphisms
that confer reduced susceptibility to BVM in phase II clinical trials.
1. Introduction
Human Immunodeficiency Virus Type 1 (HIV-1) is the
causative agent of the worldwide Acquired Immunod-
eficiency Syndrome (AIDS) epidemic. Approximately 34
million people were estimated to be living with HIV at
the end of 2010. The number of people infected is a
consequence of continued large numbers of new HIV-1
infections together with a reduction in AIDS-related deaths
due to a significant expansion in access to antiretroviral
drug therapy [1]. In the absence of an eﬀective vaccine or
cure, antiviral drugs are currently the only treatment option
available to HIV-infected patients. Therapeutic regimes com-
monly termed HAART (highly active antiretroviral therapy)
suppress viral replication but do not eradicate the virus;
therefore, treatment must be administered on a lifelong
basis [2, 3]. HAART consists of the simultaneous use of a
combination of three or four diﬀerent antiretroviral drugs.
This combinational approach is required due to the ease
with which HIV-1 can acquire drug resistance to a single
drug administered as monotherapy [3, 4]. Drug resistance
arises due to the high degree of HIV-1 genetic diversity
within the virus population (quasi-species) infecting an
individual patient. This genetic diversity is created as a
consequence of a rapid rate of viral replication combined
with the error prone nature of the viral reverse transcriptase
(RT), which copies the viral RNA genome into a double-
stranded DNA copy and the frequent recombination events
that occur during genome replication [3, 5, 6]. HAART
is possible due to the successful development and clinical
use of more than 20 antiretroviral drugs, which belong
to six diﬀerent mechanistic classes. These drugs primarily
target the viral enzymes: RT inhibitors (which fall into
two classes based on their mode of action: the nucleoside-
analog RT inhibitors (NRTIs) and nonnucleoside-analog RT
inhibitors (NNRTIs)), protease (PR) inhibitors (PIs), and
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an integrase (IN) inhibitor [7–10]. Most clinical treatment
regimens use a combination of either a PI or NNRTI with
two NRTIs, though since its approval for clinical use in 2007
the first IN inhibitor (insentress) has increasingly been used
in therapy regimens. The remaining two mechanistic drug
classes each contain one approved drug and target the viral
entry process by either blocking viral fusion by targeting
the viral gp41 envelope protein or acting as an antagonist
against the host cell coreceptor CCR5 [11]. The viral entry
inhibitors are in general reserved for salvage therapy. Salvage
therapy is required upon treatment failure primarily due to
the emergence of drug resistance and to be eﬀective should
ideally include at least one new drug targeting a novel site
of action. Until a cure for HIV infection is achieved, the
continued threat of drug resistance makes the identification
and development of a continuous pipeline of new drugs with
a novel mechanism of action an ongoing requirement [12].
In this paper we discuss protease-mediated maturation of
HIV-1 particles and the strategies to target this step in HIV-1
replication for therapeutic intervention.
2. Proteolytic Maturation and
Its Role in HIV-1 Replication
Proteolytic maturation is essential for the production of
infectious HIV-1 virus particles and has been extensively
reviewed [16–18]. Particle assembly is driven by the Gag
(Pr55Gag) polyprotein, which is transported to the cel-
lular plasma membrane where it undergoes higher-order
Gag-Gag multimerization. A second polyprotein Gag-Pol
(Pr160Gag−Pol) is also incorporated into the assembling
particle through Gag-Gag interactions. Gag-Pol is expressed
via a −1 ribosomal frameshift during approximately 5–
10% of Gag translation events. The Pol domain encodes
the viral PR, RT, and IN proteins. Gag-Gag multimerization
forces membrane curvature and assembly is completed upon
budding of the particle from the plasma membrane. Initially,
the newly formed particles have a noninfectious immature
morphology. However, concomitant with virus budding, PR
is activated to facilitate particle maturation. The exact mech-
anism of PR activation is not clearly understood, but it is
known to require Gag-Pol dimerization. Once PR is liberated
from the polyprotein through autocatalysis, it cleaves Gag
and Gag-Pol into their respective proteins. Cleavage of the
Pol domain results in the enzymatic proteins PR, RT, and IN.
Cleavage of Gag results in four protein domains: matrix (MA
or p17), capsid (CA or p24), nucleocapsid (NC or p7), p6,
and two spacer peptides SP1 (p2) and SP2 (p1) (Figure 1(a)).
Gag cleavage follows a sequential cascade that is kinetically
controlled by the diﬀerential rate of processing at each of the
five cleavage sites in Gag. The first cleavage creates an N-
terminal fragment that contains the MA-CA-SP1 domains
and a C-terminal fragment that contains the NC-SP2-p6
domains. Subsequent cleavage events occur at the MA-CA
and SP1-p6 sites and finally the CA-SP1 and NC-SP2 sites
are cleaved.
The physical consequence of Gag cleavage is a mor-
phological rearrangement of the non-infectious immature
particle to a mature infectious particle containing a conical
core, which is generated by a second assembly event upon
release of the CA domain (Figure 1(b)). The conical CA core
contains the RT and IN enzymes along with the dimeric
viral RNA genome in complex with NC and is essential for
virus replication upon infection of a new cell. Therefore,
correct core formation is essential for the production of
infectious particles and this has been shown to be dependent
on accurate proteolytic processing of Gag as mutations that
disrupt the cleavage of individual sites or alter the order
in which sites are cleaved result in aberrant particles that
have significantly reduced infectivity. The fundamental role
of proteolytic maturation in the generation of infectious
particles makes inhibiting this process an attractive target for
therapeutic intervention. In this paper we discuss how this
has been approached by (i) the successful development and
clinical use of PIs which target the PR enzyme itself and (ii)
research to develop a novel class of antiretroviral drug termed
maturation inhibitors which target the Gag cleavage sites that
act as the substrate for PR.
3. Protease Inhibitors
3.1. Introduction. Protease inhibitors (PIs) target and inhibit
the enzymatic activity of the HIV-1 PR. PIs inhibit PR
activity to the extent that is suﬃcient to prevent cleavage
events in Gag and Gag-Pol that result in the production of
non-infectious virus particles. The development of PIs in the
mid 1990s was a critical step forward in the successful treat-
ment of HIV-1 patients. This is because their development
provided a second mechanistic class of antiretroviral drug,
which made HAART combination therapy possible. PIs have
remained a key component of HIV-1 patient treatment
regimens right up to the current day. To date, nine PIs have
been approved for clinical use, they are saquinavir, ritonavir,
indinavir, nelfinavir, fosamprenavir, lopinavir, atazanavir,
tipranavir, and darunavir [8] (Table 1).
3.2. Protease Inhibitor Design. Design of PIs has been
primarily driven by structural knowledge of PR (Figure 2),
its substrate, and the chemical reaction of peptide bond
cleavage [16]. Like other retroviruses, HIV-1 PR, is related
to the cellular aspartyl PR family, which include pepsin and
renin. This family of proteases are typified by an active site
that uses two apposed catalytic aspartic acid (Asp) residues,
each within a conserved Asp-Thr-Gly motif. To function, the
cellular PRs form a pseudodimer utilizing two Asp residues
from within the same molecule to create an active site.
In contrast, retroviral PRs only contain one Asp-Thr-Gly
motif and must therefore form a true dimer. Indeed X-ray
crystallography has shown that the HIV-1 PR exists as a
dimer consisting of two identical monomers [19–21]. The
crystal structure of the dimer reveals that four-stranded β
sheets derived from both ends of each monomer hold the
dimer together. A long substrate-binding cleft is created
between the monomers and the active site is situated near
its centre with the two Asp residues located at its base. Two
β-hairpin flaps originating from each monomer cover the
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Figure 1: Proteolytic maturation of HIV-1 and its inhibition by bevirimat (BVM). (A) Gag processing cascade, illustrating the order in
which the Gag precursor is cleaved by the viral protease. Each cleavage site is indicated by a scissor symbol, the red scissor symbol depicts
the cleavage event blocked by BVM. (B) Virion morphology visualized by transmission electron microscopy (i, iii, v) and cryoelectron
tomography models generated by segmented surface rendering. The glycoprotein spikes are coloured green, the membrane and MA layer
in blue, Gag related shells in magenta, core structures in red, and other internal density in beige (ii, iv, vi). Immature particles (i and ii),
mature (iii and iv), and BVM-treated (v and vi). (C) Biochemical data demonstrating accumulation of the uncleaved CA-SP1 precursor
in virus particles in the presence of 1 μg/mL BVM. (D) Amino acid sequence at the CA-SP1 junction region; amino acids highlighted in
green indicate the highly polymorphic residues to which reduced susceptibility to BVM in clinical trials has been mapped and amino acids
highlighted in red indicate those that at which BVM resistance arises in vitro. Adapted with permission from Elsevier and the American
Society for Microbiology [12, 13].
active site and are thought to function by stabilizing the
substrate within the binding cleft.
The substrate-binding cleft interacts with multiple diﬀer-
ent substrate cleavage site sequences in Gag and Gag-Pol. The
sequence of these sites are at least seven amino acids long and
termed P4-P3′, with P1 and P1′ directly flanking the cleavage
site [16]. There is no clear consensus amino acid recognition
sequence; however, general patterns have been recognised
andmost substrate sites have a branched amino acid at the P2
site, a hydrophobic residue at P1, and an aromatic or proline
at P1′. Instead of amino acid sequence, the topology of the
cleavage site is primarily important for their recognition and
interaction with PR [22]. Each of the substrate recognition
sites has a super-imposable structure, known as the substrate
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Table 1: FDA approved protease inhibitors. Key protease resistance mutations sourced from the 2011 data review of HIV drug resistance by
the international AIDS society USA [15].
Protease inhibitor Year of FDA approval Key resistance mutations
Saquinavir 1995 G48V, L90M
Ritonavir 1996 Used for boosting
Indinavir 1996 M46I/L, V82A/F/T, I84V
Nelfinavir 1997 D30N, L90M
Fosamprenavir 1999 I50V, I84V
Lopinavir 2000 V32I, I47V/A, L76V, V82A/F/T/S
Atazanavir 2003 I50L, I84V, N88S
Tipranavir 2005 I47V, Q58E, T74P, V82L/T, N83, I84V
Darunavir 2006 I47V, I50V, I54M/L, V76V, I84V
Figure 2: Three-dimensional structure of the HIV protease dimer
in complex with the protease inhibitor saquinavir bound at the
active site. Adapted by Jerry Alexandrators with permission from
Annual Reviews [14].
envelope, which fits within the PR substrate-binding cleft.
The divergent amino acid sequences of substrate recognition
sites do however result in subtle structural diﬀerences, which
are caused by diﬀerent side chain protrusions from the
substrate envelope. These side chains extend into pockets or
subsites in the substrate-binding cleft. Each subsite is named
for the corresponding substrate side chain, for example, the
S1 subsite corresponds to the P1 side chain. These diﬀerences
are thought to alter the rate at which cleavage occurs at
individual sites in Gag facilitating the regulated proteolytic
processing cascade of Gag that is essential for correct particle
formation.
The catalytic mechanism of substrate cleavage requires
the Asp residues to coordinate a water molecule that is
used to hydrolyze the target peptide (scissile) bond [23].
During the reaction, a transition state intermediate is formed
which has been mimicked in the design of most PIs,
which are peptidomimetic transition-state analogues. The
principle of this design strategy is that the normal peptide
linkage [–NH–CO–] is replaced by a hydroxyethylene group
[–CH2–CH(OH)–], which cannot be cleaved by simple
hydrolysis. Saquinavir was the first PI to be approved for
clinical use and its design is based on this principle. The
following PIs ritonavir, indinavir, nelfinavir, amprenavir,
lopinaivr, atazanavir, fosamprenavir, and darunavir also all
contain a central core motif of a hydroxyethylene scaﬀold.
The exception is tipranavir, which has a coumarin scaﬀold
and is therefore the only clinically approved PI, which is not
a peptidomimetic [8]. Knowledge of the catalytic mechanism
and a strategy to generate a transition state analogue was
coupled with the ability to cocrystallize candidate inhibitors
in complex with PR. This facilitated structure-based drug
design that enabled consecutive rounds of lead optimization
to develop inhibitors, which competitively bind the active
site with aﬃnities to purified PR in the low nanomolar to
low picomolar range. The rational design strategy was also
used to develop inhibitors that aim to combat problems
encountered in the clinic, including poor bioavailability,
aberrant side eﬀects, and drug resistance.
3.3. Clinical Application and Resistance. Clinical use of PIs
began in 1995 with the FDA approval of saquinavir [8].
Saquinavir’s approval was closely followed by ritonavir and
indinavir in 1996 and nelfinavir in 1997 [8]. In vitro studies
demonstrated that all of these “first generation” PIs inhibit
HIV-1 replication in the nanomolar range in a selection of
cell types relevant to HIV-1 infection [24–27]. Initial clinical
trials with these drugs were conducted as monotherapy
and encouragingly demonstrated declines in HIV-1 RNA
levels although the antiviral eﬀect was not sustained for
long periods of time due to the rapid acquisition of drug
resistance [28–33]. Improved and more sustained reductions
in viral RNA levels along with increased CD4 cell counts
were obtained when a PI was included in triple therapy
combinations with two NRTIs [34–40]. Importantly, these
triple-drug regimens (HAART) significantly reduced disease
progression and mortality in HIV/AIDS patients [8, 38].
Therefore, the development of PIs facilitated a pivotal step
forward in the clinical management of HIV/AIDS and
dramatically improved the clinical outcome of the disease.
Despite the successes, antiviral suppression was not
always durable and these early clinical trials highlighted a
number of key problems associated with PIs. As indicated
above, drug resistance was problematic from the outset and
the complex mechanisms of resistance will be discussed
in more detail below. Acquisition of drug resistance was
compounded by problems with adverse side eﬀects (abnor-
mal lipid and glucose metabolism) and low bioavailability
(typical of peptide-like molecules), which led to suboptimal
Molecular Biology International 5
drug concentrations, high pill burdens, and diﬃculties with
patient adherence to treatment regimens [8]. A notable
observation to help overcome the pharmacological problems
was that ritonavir acts as a potent inhibitor of the cytochrome
P450 3A4 metabolic pathway [41]. As a consequence it
has been demonstrated that coadministering a low non-
therapeutic dose of ritonavir with other PIs leads to dra-
matically improved bioavailability, half-life, and potency of
these PIs [41]. Ritonavir boosting has become a standard
procedure when using most PIs in the clinic.
The next generation of PIs aimed to improve upon the
problems highlighted above. The first was amprenavir, which
was approved for clinical use in 1999, next came lopinavir
which was approved in 2000, followed by atazanavir in 2003,
tipranavir in 2005, and lastly darunavir in 2006 [8]. In 2003
amprenavir was subsequently reformulated as the prodrug
fosamprenavir, which improved drug plasma concentrations
and aﬀorded a lower pill burden [42]. Reduction in pill
burden was also achieved by the coformulation of lopinavir
with a low dose of ritonavir and further progress in the
simplification of drug regimens came with atazanavir, which
was the first PI with a once daily dosing regimen. Drug
potency has also been improved, in vitro studies have shown
atazanavir and darunavir to be particularly potent with IC50
values of between 1 and 5 nM however, tipranavir is the least
potent because of its novel nonpeptidomimetic chemical
structure [43–47]. Clinical trials demonstrated that the next
generation PIs performed well with superior virological
eﬃcacy when tested against a placebo or another comparator
PI in a background of two NRTIs [8, 48–52]. Finally many of
these PIs acquire diﬀerent drug resistance mutation profiles
from the earlier PIs and/or have a higher genetic barrier to
resistance.
Resistance has been encountered for all nine PIs and has
been extensively reviewed [8, 53–55]. A current summary of
the key mutations acquired by each of them is provided in
a data review of HIV-1 drug resistance by the International
AIDS Society-USA [15]. The genetic barrier for acquisition
of PI resistance is relatively high, that is, it requires two or
more amino acid changes to confer significant resistance.
This is because PI drug resistance is a stepwise pathway
that results in complex interdependent combinations of
multiple mutations. All of these interdependent changes are
required to act in synergy to confer drug resistance whilst
simultaneously maintaining the fitness of the virus.
The mutations that arise first are referred to as primary
or major mutations and they are usually located in the
PR substrate-binding cleft or its immediate vicinity. Exam-
ples of primary mutations include D30N, G48V, I50L/V,
V82A/F/L/S/T, I84V, and L90M [15]. These primary muta-
tions are principally responsible for acquisition of drug
resistance by causing conformational changes in and around
the active site that prevent inhibitor binding [53]. More
specifically, PIs bound to the substrate-binding cleft occupy
a similar space as the substrate envelope, but atoms of the
PI protrude from this space and interact with residues in
PR. Therefore, it has been proposed that drug resistance
mutations arise at PR residues involved in these points
of contact to inhibit PI binding [56]. In addition to the
direct mechanism of resistance described above resistance-
conferring mutations may also result in conformational
changes to PR beyond the active site and nonactive site
mutations can also contribute to drug resistance [53].
Recently rare amino acid insertions, particularly between
residues 32 and 42 have been observed to occur more
frequently and in correlation with the introduction of
atazanavir, lopinavir, amprenavir, and tipranavir into the
clinic. The insertions have been proposed to be associated
with PI resistance by imposing minor structural changes
to the PR flap and substrate-binding cleft, although they
always appear in combination with other well-described PI
resistance mutations [57].
Primary mutations are accompanied by secondary or
minor mutations, which can be preexisting polymorphisms
or acquired after primary mutations. The function of
many of these secondary mutations is often not to confer
drug resistance per se but instead to compensate for the
eﬀect of primary mutations, which reduce protease catalytic
eﬃciency and virus replication capacity or fitness [58–62].
Despite their function being less drug specific in action, they
are however critical for development of high-level resistance.
The secondary mutations are generally located at residues
distal from the active site and occur at more than 20 residues
of PR [15]. Unlike the primary mutations, which generally
occur at highly conserved residues, the secondary mutations,
are often polymorphic in PI treatment-naı¨ve patient isolates,
a well-documented example is the L63P substitution [58],
and thus favour the selection of primary mutations in the
presence of drug. Despite the presence of multiple secondary
mutations almost all clinical strains of HIV-1 with high-
level PI drug resistance display some degree of fitness loss
[58, 61, 63, 64].
Resistance to PIs is a compromise between resistance
and PR enzyme function. The mutations in PR described
above primarily have an impact on inhibitor binding while
still allowing the enzyme to recognise and cleave its Gag
and Gag-Pol substrates to some degree. In addition to
the changes in PR itself, amino acid changes in the Gag
substrate have also been described [54]. These mutations
are primarily located at or near to Gag cleavage sites and
more specifically the sites in the NC-SP2-p6 region of Gag.
Key mutations observed at the NC-SP2 cleavage site are
A431V and I437V, which are commonly found in association
with the PR primary mutation V82A and key mutations
observed at the SP2-p6 cleavage site are L449F and P453L,
which are commonly found in association with the PR
primary mutations I50V and I84V [65–72]. In vitro selection
experiments have also shown that mutations at the NC-SP2
cleavage site (A431V, K436E, and/or I437V/T) can also be
selected in the presence of PIs without any accompanying
resistance mutations in PR [73]. Mutations in Gag located at
positions distal to cleavage sites have also been documented
[74–76]. The impact of mutations in Gag has been attributed
to (i) acting as compensatory mutations that improve fitness
defects imposed by PI resistance-conferring mutations in PR
and (ii) directly contributing to PI resistance [65–67, 73,
77]. The mechanism by which Gag cleavage-site mutations
compensate for a loss in viral fitness is by improving the
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interaction between the substrate and the mutant enzyme
and hence increasing the ability of the mutant PR to cleave
[78]. Noncleavage site mutations are thought to improve
fitness by causing more broad conformational changes in
Gagmaking cleavage sites more accessible to PR [74–76]. The
mechanism by which Gag cleavage-site mutations directly
contribute to PI resistance is however not clearly understood
[54].
Despite the complex interdependent combinations of
multiple mutations in both PR and its Gag substrate that
are required to attain high-level PI drug resistance, many
of the PIs have a distinctive primary mutation that can be
considered a signatory of drug resistance to that particular
PI. For example the D30N mutation is a signatory of
nelfinavir resistance, I50L is a signatory of atazanavir resis-
tance, the I50V mutation is a signatory of amprenavir and
darunavir resistance, and the G48V mutation is a signatory
of saquinavir resistance [15]. Unfortunately, however, many
mutations confer drug resistance to multiple PIs leading to
broad cross-resistance amongst most PIs [15]. For example,
the I84V mutation is the most important as it aﬀects all
eight PIs in clinical use and acts as a key mutation for five
of them (atazanavir, darunavir, fosamprenavir, indinavir, and
tipranavir). Mutations at residue 82 aﬀect all of the PIs except
darunavir. The I54V substitution acts as a key mutation
for darunavir but it also aﬀects all the other PIs with
the exception of nelfinavir and the L90M mutation aﬀects
PIs with the exception of darunavir and tipranavir. Cross-
resistance is likely due to the fact that although chemically
diﬀerent, most of the PIs were designed using the same basic
principle and have similar structures and interactions with
the PR substrate-binding cleft. Extensive cross-resistance has
serious clinical consequences that threatens the usefulness of
PIs and drives an ongoing need for new PIs with improved
resistance profiles.
3.4. Conclusion. The introduction of PIs into the clinic
more than 15 years ago heralded the era of HAART
and resulted in a significant reduction in morbidity and
mortality among HIV-infected patients. Due to their clinical
potency, PIs are still commonly used in treatment regimens,
although only three (lopinavir, atazanavir and darunavir)
of the nine approved PIs are in widespread use. Despite
the clinical benefits, the usefulness of first generation PIs
was particularly hampered by toxic side eﬀects and low
bioavailability, which resulted in high pill burdens and
low patient adherence. A significant advance in resolving
these issues was the introduction of low-dose ritonavir
boosting, which increases plasma PI levels by inhibiting the
cytochrome P450 metabolic pathway. Ritonavir-boosting is
itself; however, associated with toxicity; therefore, alternative
boosting compounds with improved properties are being
developed.
PI drug resistance is a major cause of therapy failure
despite the relatively high genetic barrier to resistance.
Unfortunately, PR has proven to be a highly flexible and
adaptable drug target due to diverse mutational profiles and
the complex interplay between PR and its Gag substrate.
Extensive cross-resistance to PIs has also been a key problem
that has limited the overall usefulness of the drug class
despite the development of new inhibitors such as darunavir
with favourable resistance profiles. Therefore, there is a need
to develop further novel inhibitors with improved resistance
profiles to address these ongoing issues [79]. One strategy to
develop such new PIs is to build on the design of existing
inhibitors that target the PR active site by introducing
novel modifications to established PI chemical entities. One
such example is the novel inhibitor GS-8374, which is a
modification of a darunavir-like analogue [80]. GS-8374 has
been shown to be highly potent with a resistance profile
superior to all clinically approved PIs including the parent
molecule darunavir [80]. A second strategy is to identify
molecules with novel chemical scaﬀolds, for example PPL-
100 is a nonpeptidomimetic inhibitor that incorporates a
new lysine-based scaﬀold and binds the flap region of PR
via a novel mechanism [81]. PPL-100 has been shown
to have a favourable resistance profile against known PI
resistant HIV-1 isolates and its in vitro selection pattern
results in two previously undocumented mutations T80I and
P81S together with two previously reported compensatory
mutations K45R and M46I [81, 82]. Allosteric inhibitors that
bind a site other than the PR active site via a noncompetitive
mechanism of action have also been identified and shown to
be eﬀective against both wildtype and PI resistant purified PR
[83]. A further novel strategy, discussed below, is to design
inhibitors that prevent proteolytic maturation by targeting
the Gag substrate rather than the PR enzyme itself.
4. Maturation Inhibitors
4.1. Introduction. PIs directly target the PR enzyme; however,
an alternative approach to inhibiting HIV-1 proteolytic
maturation is to identify small molecules that bind its
Gag substrate and specifically block individual cleavage
events. Such a strategy would be successful because accurate
proteolytic processing of Gag is essential for the production
of infectious particles as mutations that disrupt the cleavage
of individual sites or alter the order in which sites are
cleaved result in aberrant particles that have significantly
reduced infectivity. Molecules with this mechanism of action
have been termed maturation inhibitors and the first-in-
class is 3-O-(3′,3′-dimethylsuccinyl)betulinic acid (DSB),
also known as PA-457, MPC-4326, or bevirimat (BVM).
4.2. Mechanism of Action. BVM specifically inhibits CA-
SP1 cleavage, which occurs late in the Gag proteolytic
cleavage cascade [84, 85]. This has been demonstrated
by a number of key observations: (i) biochemical studies
have demonstrated an accumulation of the uncleaved CA-
SP1 intermediate in both cell and virus-associated protein
fractions from HIV-1 expressing cells treated with BVM [84–
86] (Figure 1(c)); (ii) viruses such as HIV-2 and SIV which
have a divergent sequence at the CA-SP1 junction are not
sensitive to BVM [87]; (iii) the majority of BVM drug-
resistance conferring mutations map to the CA-SP1 junction
or within SP1 [84–86, 88–95]. A second molecule PF-46396
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has been identified that also inhibits CA-SP1 cleavage [96].
Interestingly, although PF-46396 has a similar mechanism of
action as BVM, it belongs to a distinct chemical class as it is
a pyridone-based compound not a betulinic acid derivative
like BVM [96].
The consequence of BVM blocking SP1 cleavage from
the C-terminus of CA is the formation of noninfectious
particles with an aberrant morphology [84] (Figure 1(b)).
Three-dimensional (3D) imaging of BVM-treated particles
by cryoelectron tomography showed that they contain an
incomplete protein shell, which has a hexagonal honeycomb
lattice in the CA layer that is similar in structure to the Gag
lattice of immature virus particles [13]. This partial shell is
consistent with the aberrant electron dense crescent inside
the viral membrane observed in BVM-treated particles by
conventional thin-sectioning electron microscopy [84]. Both
imaging techniques also showed most BVM-treated particles
to contain an acentric mass, which represents an abnormal
core-like structure [13, 84]. The general morphological
features of BVM-treated particles are shared by particles
generated by the CA5 mutant, which has two amino acid
substitutions that completely block CA-SP1 cleavage [84, 97].
However, these particles have a thinner CA layer with no
visible evidence of honeycomb lattice organization [13].
The presence of structural organization in the BVM-treated
but not the CA5 CA layer suggests that BVM binding
stabilizes the immature lattice as well as blocking CA-SP1
cleavage and that both modes of action may potentially
contribute to the generation of non-infectious particles
[13].
The assembly state of Gag is a determinant of BVMs
activity. BVM does not inhibit CA-SP1 processing in the
context of monomeric Gag in solution [84], but instead
requires Gag assembly for its activity [84, 98, 99]. Therefore,
it can be hypothesized that BVM binds to a pocket formed
during Gag-Gag multimerization. Conversely, Gag process-
ing disrupts the putative binding site because BVM has been
shown to bind immature but not mature HIV-1 particles
[99]. The BVM binding site has been mapped to the CA-SP1
junction within immature virus particles using photoaﬃnity
BVM analogues and mass spectroscopy [100]. This provides
the first direct evidence that the BVM binding site spans the
CA-SP1 junction and is consistent with previous biochemical
and genetic data that have implicated this region of Gag
in BVM binding. Indeed, BVM binding is disrupted in a
selection of BVM-drug resistant mutations with amino acid
substitutions that map to the CA-SP1 junction [100, 101].
Positioning of BVM across the CA-SP1 junction supports
a mechanism of action whereby binding blocks access of
the viral PR to the CA-SP1 cleavage site. A second related
hypothesis is that BVM binding alters the conformation,
exposure, or flexibility of this region such that PR cleaves
it less eﬃciently. The binding study [100] also identified a
second BVM binding site in the major homology region
(MHR) of CA, a region of Gag known to function in virus
assembly [17]. The significance of a potential second BVM
binding site has yet to be established but may provide an
explanation for the observation that at high concentrations
BVM inhibits virus particle assembly [102].
The structure of the BVM binding site remains unknown
because this region of Gag has been disordered in X-
ray crystallographic studies [103, 104]. The disorder has
been attributed to a structural flexibility, which permits
higher-order Gag-Gag multimerization during virus particle
assembly [105–110]. It is, however, generally accepted that
the CA-SP1 region of Gag adopts a α-helical conformation.
The evidence for a helical structure is based on (i) secondary
structure computer modelling predictions [111], (ii) genetic
data demonstrating that mutation of key residues predicted
to be helix breakers results in a disruption of virus par-
ticle assembly [106, 111] and (iii) biophysical and NMR
techniques that have shown the CA-SP1 region to have a
propensity to adopt a helical conformation under certain
environmental conditions [110, 112, 113]. Although the
interactions formed by the proposed CA-SP1 junction helices
in the Gag lattice are not known, a cryoelectron tomography
study of immature particles led to the hypothesis that the
CA-SP1 region exists as a six-helix bundle that lies directly
below the hexagonal honeycomb CA lattice [114]. Because
BVM activity is known to require higher-order Gag-Gag
multimerization, it has been suggested that the BVM binding
pocket might involve more than one helix and hence bound
BVM may occupy a cleft formed between helices [100].
The considerable technical challenges of obtaining high-
resolution structural information of the CA-SP1 junction
in the context of higher-order multimerized Gag make the
prospect of rational drug design using inhibitor cocomplexes
not currently possible. However, further understanding of
the interactions involved is important for the develop-
ment of second-generation maturation inhibitors. Such new
molecules are now required as clinical development of BVM
was suspended in 2010 due to problems with intrinsic BVM
drug resistance in HIV-1 infected patients during phase II
clinical trials.
4.3. Clinical Development and Resistance. BVM was consid-
ered an attractive candidate for clinical development because
of its potent in vitro activity with amean IC50 value of 10 nM
and its novel mechanism of action, which makes it equally
eﬀective against viruses that have acquired resistance to key
antiretroviral drugs in clinical use [84]. Additional attributes
including promising pharmacological and safety studies in
animal models and phase I clinical trials [115] led to the
testing of BVM in HIV-1 infected patients. Initial success
in these phase II clinical trials demonstrated significant
BVM dose-dependent viral load reductions [115]. However,
further studies quickly showed that approximately 50% of
BVM-treated patients did not eﬀectively respond to the
drug and exhibited viral load reductions of less than 0.5 log
[93]. Failure to respond was not due to suboptimal BVM
plasma concentrations but has been attributed to virological
parameters instead.
Examination of patient-derived virus revealed amino
acid assignment at SP1 residues 6, 7, and 8 (Gag positions
369, 370, and 371) is associated with response to BVM
[92, 93, 95] (Figure 1(d)). This trio of residues map to the
C-terminal half of SP1, which is relatively nonconserved
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but commonly encodes a QVT (glutamine-valine-threonine)
motif in clade B HIV-1 isolates [95]. Patients most likely
to respond to BVM are infected with virus encoding the
QVT motif, while patients infected with virus encoding
polymorphisms at SP1 residues 6–8 are less likely to respond
[93]. Studies to investigate the contribution of individual
substitutions at SP1 residues 6–8 have shown that mutations
at SP1 residue 7 and 8 (e.g., SP1-V7A, -V7M, -T8Δ,
-T8N) all confer varying degrees of reduced susceptibility
to BVM [88, 92, 94, 95]. Most notably, a critical role
for BVM resistance has been attributed to the SP1-V7A
polymorphism as it confers full resistance to BVM [88,
92, 94, 95]. BVM susceptibility was not however reduced
by mutations at SP1 residue 6 (e.g., SP1-Q6H, Q6A) or
the SP1-T8A polymorphism [88, 92, 94, 95]. Therefore,
any contribution of these substitutions to reduced BVM
susceptibility maybe dependent on the synergistic eﬀects of
a combinations of diﬀerent polymorphisms, i.e. the context
of the wider Gag background. Indeed, one study identified
five patient-derived virus samples with significantly reduced
BVM susceptibility in vitro but still encoded the QVT motif
[92]. In two of these isolates, BVM resistance has been
demonstrated to be conferred by a polymorphism in CA
(CA-V230I) situated at the P2 position of the CA-SP1
cleavage site [92] (Figure 1(d)). In the other three isolates,
the determinants of reduced BVM susceptibility were not
resolved [92], indicating that in some instances the factors
conferring BVM susceptibility are likely to be more complex
than the parameters that have been established to date.
The CA-V230I and SP1-V7A substitutions have also
been acquired in in vitro BVM drug-resistance selection
experiments [88, 90, 91]. In vitro studies have also identified
a panel of other BVM-resistance mutations (CA-H226Y, CA-
L231M, CA-L231F, SP1-A1V, SP1-A3V, and SP1-A3T) [84–
86, 90] (Figure 1(d)). Unlike, the clinically important innate
polymorphisms discussed above, these in vitro selected
BVM-resistance mutations map to residues in the vicinity
of the CA-SP1 cleavage site that are highly conserved
throughout HIV-1 isolates [86]. As a likely consequence,
these mutations have not been observed in most patient-
derived virus samples either with [93, 95] or without BVM
treatment [92, 95]. However, it should be noted that themost
frequently acquired mutation SP1-A1V has been shown not
to impose a significant defect on virus replication in vitro
[86, 89, 90] and replicates eﬃciently in SCID-hu Thy/Liv
mice [116]. Therefore, it remains a hypothetical possibility
that the SP1-A1V mutation could be acquired over time in
patients that initially respond well to BVM treatment.
Initial failure to select the key BVM-resistance conferring
polymorphisms in vitro has been attributed to the experi-
mental conditions utilized [91]; however, later experiments
did result in selection of some of the key polymorphic
mutations albeit at low frequency [88, 90]. Nevertheless,
a recent study used a more sophisticated in vitro method
of serial passage of quasi-species containing recombinant
HIV-1 and deep sequencing that more accurately mimicked
in vitro the selection of BVM-resistance observed in vivo
[91]. In hindsight use of this in vitro selection method
or more extensive testing of the spectrum of activity
across a diverse panel of clinical isolates may have more
accurately predicted the clinical response to BVM and either
led to discontinuation of BVM development at an earlier
stage thereby avoiding costly clinical studies or alternatively
steered BVM’s clinical development to include a genotyping
test to screen for preexisting key polymorphisms to enable
prior identification of patients most likely to eﬀectively
respond to BVM treatment [91].
The clinically important polymorphisms preexist in
the HIV-1 population without prior BVM treatment. This
intrinsic resistance has caused problems for BVM’s clinical
development, which was consequently discontinued in 2010.
Genotypic analysis has demonstrated a high prevalence of
polymorphisms at the QVT motif and their frequency is
dependent on the genetic clade of HIV-1 [94, 95, 117].
In clade B viruses, which are predominant in the US and
Europe, polymorphism frequency at the QVT motif has been
reported to occur at a rate of ∼30–60% [91, 95, 117]. This
genotypic analysis matches BVM susceptibility rates in the
in vitro phenotypic and clinical trial studies discussed above
[92, 93, 95]. In nonclade B viruses, QVT polymorphism rates
are much higher with rates of >90% [95, 117]. Typically
polymorphisms occur most frequently at SP1 residue 7,
followed by residue 8, and then residue 6 [91, 94, 95]. The
critical SP1-V7A polymorphism has been shown to be largely
predominant and occurs at a frequency of ∼16% in clade B
viruses and ∼65–70% in clade C viruses, which are mostly
found in Southern Africa [94, 95]. The high frequency of the
SP1-V7A polymorphism combined with its known capacity
to confer full resistance to BVM therefore poses the biggest
threat to the potential eﬀectiveness and clinical development
of BVM.
The prevalence of the key polymorphisms in relation to
HAART and the presence of PI resistance mutations has been
investigated due to the complex interplay between PR and
its Gag substrate. Being a new class of antiretroviral drug
BVM was most likely in the first instance to be used as
salvage therapy for patients harbouring multidrug resistant
HIV-1 isolates. Studies have shown no association between
the prevalence of key QVT polymorphisms and HAART
treatment experience but in the absence of BVM [91, 92,
117]. One study also reported no association between preva-
lence of QVT polymorphisms and PI resistance-conferring
mutations [92]; however, two other studies with bigger
sample sizes demonstrated a higher frequency of BVM
resistance mutations in PI resistant patient isolates [117,
118]. The eﬀect of PI resistance on acquisition of BVM
resistance in vitro has also been investigated [89, 90]. These
two studies made diﬀerent conclusions about the impact
of the PI mutations on the temporal acquisition of BVM-
resistance conferring mutations, with one study reporting a
delay in the emergence of BVM-resistance [89]. The reported
diﬀerences may be dependent on the type of PI mutations
or the study systems used. Interestingly, the other study
[90] demonstrated that the PR background influenced the
type and diversity of BVM resistance conferring mutations.
Viruses with a wildtype PR predominantly acquired the
SP1-A1V mutation, whereas viruses with a PI resistance
PR acquired a significantly higher prevalence of mutations
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at the QVT motif (SP1-V7A, V7N, and SP1-T8N), at
the polymorphic CA-230 residue (CA-V230I) and also a
previously unreported mutation SP1-S5N. The PR genetic
background was also found to eﬀect BVM susceptibility
and virus replication capacity [90]. While these studies
have not fully resolved the complex interplay between PR,
the Gag substrate and susceptibility to BVM they clearly
demonstrate that this parameter should be considered in
future development of maturation inhibitors.
4.4. Conclusion. Maturation inhibitors are a novel mech-
anistic class of antiretroviral drug that target PR cleavage
sites in Gag. BVM is the first-in-class maturation inhibitor,
which specifically inhibits cleavage of SP1 from the C-
terminus of CA. A number of other small molecules that
target Gag have also been identified. PF-46396 is a second
maturation inhibitor, which also inhibits CA-SP1 cleavage
but is chemically distinct from BVM. There are also a small
number of molecules that target CA and inhibit assembly
of the immature particle and/or the CA core [12]. BVM
is however the only molecule that targets Gag, which has
been tested in clinical trials. BVM was considered a good
candidate for clinical development because of its in vitro
potency, novel mechanism of action, and good safety profile
in animal models and phase I clinical trials. Although initial
results of BVM eﬃcacy in HIV-1 infected patients were
encouraging, it was quickly established that approximately
50% of patients do not eﬀectively respond to the drug.
Failure to respond is due to virological parameters, more
specifically, intrinsic polymorphisms primarily located at
SP1 residues 6, 7, and 8. These polymorphisms have a high
prevalence, particularly in non-clade B HIV-1 isolates. The
existence of BVM-resistance conferring polymorphisms in
BVM-treatment naı¨ve patients severely limits the clinical
usefulness of BVM and consequently clinical development of
BVM was suspended in 2010.
Halted clinical development of BVM necessitates the
need for a second-generation maturation inhibitor to over-
come the problem of intrinsic drug resistance encountered
by BVM. BVM targets an as yet undefined drug-binding
pocket, which is hypothesized to be created upon higher-
order multimerization of Gag during virus particle assem-
bly. The significant technical challenge of obtaining high-
resolution structural information of this hypothetical drug
target makes rational structure-based drug design unfeasible
at the current time. However, the need to develop improved
maturation inhibitors has highlighted a need to further
our understanding of the CA-SP1 region of Gag and its
role in HIV-1 particle assembly. BVM, PF-46396, and their
analogues can be utilized as tools to further explore drug-
binding requirements to inform future strategies to improve
drug resistance profiles. Development of BVM has provided
evidence that small molecules to inhibit HIV-1 replication
can target Gag cleavage sites. Four other cleavage sites are
present in Gag and a genetic study predicted that a small
molecule that blocks MA-CA cleavage maybe a particularly
potent inhibitor of HIV-1 replication [119]. However, the
intrinsic flexibility in Gag cleavage sites and wide variation
in substrate sequence recognition by HIV PR may represent
insurmountable problems for the future development of
maturation inhibitors.
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